Q-omics provides the consensus-scored MIR652 profile across patient tissues and cancer cell-line models. MIR652 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR652 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR652 RNA expression shows 7,334 significant gene co-expression associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, BRCA, and LUAD as cancer lineages where MIR652 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR652 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR652 survival associations across molecular data types. MIR652 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR652 RNA expression–survival associations across cancer types. High MIR652 expression shows unfavorable associations in MESO and PAAD, but favorable associations in HNSC, SKCM and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR652 RNA expression.
This table summarizes MIR652 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR652. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR652 shows higher tumor expression in BRCA. The BRCA box plot shows higher MIR652 RNA expression in tumor versus normal tissue (log2 FC = +0.137, t-test p = .022).
This table shows molecular features associated with MIR652 in patient tissues and cancer cell lines. In patient samples, MIR652 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
